Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Rachel Montgomery"'
Autor:
Pedro C Barata, Andrea Leith, Amanda Ribbands, Rachel Montgomery, Matthew Last, Bhakti Arondekar, Jasmina Ivanova, Alexander Niyazov
Publikováno v:
The Oncologist.
Background There is limited real-world evidence on how increasing use of treatment intensification in metastatic castration-sensitive prostate cancer (mCSPC) has influenced treatment decisions in metastatic castration-resistant prostate cancer (mCRPC
Autor:
Pedro C Barata, Andrea Leith, Amanda Ribbands, Rachel Montgomery, Matthew Last, Bhakti Arondekar, Jasmina Ivanova, Alexander Niyazov
Publikováno v:
The Oncologist.
Background Continuous androgen deprivation therapy ± first-generation non-steroidal antiandrogen was previously the standard-of-care for patients with metastatic castration-sensitive prostate cancer (mCSPC). Treatment intensification with novel horm
Autor:
Jane Chang, Nuno Costa, Mairead Kearney, Caspian Kluth, Callum Bleasdale, Rachel Montgomery, Melissa Kirker, Mia Unsworth, Neil Milloy, Maria Lapuente
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0310017d9ba8ee4c72bb90d2f7324cec
https://doi.org/10.26226/m.631864567e215f5e7f3852b3
https://doi.org/10.26226/m.631864567e215f5e7f3852b3
Autor:
Pedro C. Barata, Rachel Montgomery, Matthew Last, Liane Gillespie-Akar, Jonathan Nazari, Alexander Niyazov
Publikováno v:
Journal of Clinical Oncology. 41:99-99
99 Background: A subset of pts with metastatic prostate cancer have HRR mutations. These can be either germline or somatic mutations. Previous studies have established a prognostic and predictive role of HRR mutations and there are ongoing trials (e.
Autor:
Amur Margaryan, Vanik Kakoyan, Simon Zhamkochyan, Sergey Abrahamyan, Hayk Elbakyan, Samvel Mayilyan, Henrik Vardanyan, Hamlet Zohrabyan, Lekdar Gevorgian, Robert Ayvazyan, Artashes Papyan, Garnik Ayvazyan, Bagrat Grigoryan, John Annand, Kenneth Livingston, Rachel Montgomery, Patrick Achenbach, Josef Pochodzalla, Dimiter L. Balabanski, Satoshi N. Nakamura
Publikováno v:
Nuclear Instruments and Methods in Physics Research Section A: Accelerators, Spectrometers, Detectors and Associated Equipment. 1038:166926
This paper describes a new radio frequency timer of keV energy electrons. It is based on a helical deflector, which performs circular or elliptical sweeps of keV electrons, by means of 500 MHz radio frequency field. By converting a time distribution
Autor:
Pedro C. Barata, Andrea Leith, Amanda Ribbands, Rachel Montgomery, Matthew Last, Bhakti Arondekar, Alexander Niyazov, Jasmina Ivanova
Publikováno v:
Journal of Clinical Oncology. 40:52-52
52 Background: Novel hormonal therapies (NHTs) and docetaxel were initially approved for the tx of men with mCRPC. Over time, these agents moved earlier in the disease continuum and are now also used in metastatic castration sensitive prostate cancer
Autor:
Neil Milloy, Melissa Kirker, Mia Berry, Michael Kostikas, Rachel Montgomery, Mairead Kearney, Nuno Matos Costa, Jane Chang
Publikováno v:
Journal of Clinical Oncology. 40:457-457
457 Background: European Society for Medical Oncology (ESMO) guidelines recommend tx for mUC based on cisplatin and platinum eligibility. To date, most real-world analyses have not included physician-confirmed eligibility status. This study collected
Autor:
Edward I Broughton, Jürgen E. Gschwend, J. Alfred Witjes, Mia Berry, Michael Kostikas, Rachel Montgomery, Annabel Lambert, Siguroli Teitsson, Neil Milloy
Publikováno v:
Journal of Clinical Oncology. 40:467-467
467 Background: Cisplatin-based neoadjuvant chemotherapy (NAC) followed by RR is the standard of care in cisplatin-eligible pts with MIUC. Adjuvant chemotherapy (AC) with cisplatin-based tx may be offered to those not given NAC. The unmet need this s
Autor:
Pedro C. Barata, Andrea Leith, Amanda Ribbands, Rachel Montgomery, Matthew Last, Bhakti Arondekar, Alexander Niyazov, Jasmina Ivanova
Publikováno v:
Journal of Clinical Oncology. 40:66-66
66 Background: Novel hormonal therapies (NHTs) and taxane-based chemotherapy (CT) were initially approved for the treatment of metastatic castration resistant prostate cancer (mCRPC) and are now approved for use in mCSPC. Little is known about the re
Publikováno v:
Contact Dermatitis. 78:33-40
SummaryBackground Fragrances are well known to cause allergic contact dermatitis (ACD). Occupationally related cases occur, with certain groups being at higher risk. Objective To investigate the incidence of occupationally related cases of cutaneous